• 1
    Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centred approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2012;35:13641379.
  • 2
    American Diabetes Association. Standards of medical care in diabetes–2012. Diabetes Care, 2012;35:S11S63.
  • 3
    Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology, 2007;132:21312157.
  • 4
    Nauck MA. Unraveling the science of incretin biology. Am J Med, 2009;122:S3S10.
  • 5
    Laferrere B. Gut feelings about diabetes. Endocrinol Nutr, 2012;59:254260.
  • 6
    McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet, 1964;284:2021.
  • 7
    Elrick H, Stimmler L, Hlad CJ, Arai Y. Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab, 1964;24:10761082.
  • 8
    Phillips LK, Prins JB. Update on incretin hormones. Ann N Y Acad Sci, 2012;1243:E55E74.
  • 9
    Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes, 1995;44:11261131.
  • 10
    Cornell S. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. J Clin Pharm Ther, 2012;37:510524.
  • 11
    Cornell S. Key considerations in pharmacotherapy for type 2 diabetes mellitus: a multiple target organ approach. J Clin Pharm Ther, 2012;37:254259.
  • 12
    Morales J. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. Postgrad Med, 2011;123:189201.
  • 13
    DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, Macconell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin, 2008;24:29432952.
  • 14
    Berg JK, Shenouda SK, Heilmann CR, Gray AL, Holcombe JH. Effects of exenatide twice daily versus sitagliptin on 24-hour glucose, glucoregulatory, and hormonal measures: a randomized, double-blind, crossover study. Diabetes Obes Metab, 2011;13:982989.
  • 15
    Neumiller JJ, Campbell RK. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother, 2009;43:14331444.
  • 16
    Russell-Jones D, Cuddihy RM, Hanefeld M et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care, 2012;35:252258.
  • 17
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998;352:837853.
  • 18
    UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS): VIII. study design, progress and performance. Diabetologia, 1991;34:877890.
  • 19
    Eeg-Olofsson K, Eliasson B, Zethelius B, Svensson A-M, Gudbjornsdottir S, Cederholm J. HbA1c reduction and risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish NDR. Diabetes, 2012;61:A108.
  • 20
    Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet, 2009;374:3947.
  • 21
    Buse JB, Nauck MA, Forst T et al. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study. In: Program and abstracts of 47th Annual Meeting of the European Association for the Study of Diabetes; September 12–16. Portugal, Lisbon: 2011; Abstract 75.
  • 22
    Blevins T, Pullman J, Malloy J et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab, 2011;96:13011310.
  • 23
    Drucker DJ, Buse JB, Taylor K et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet, 2008;372:12401250.
  • 24
    Raskin P, Mohan A. Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial). Expert Opin Pharmacother, 2011;11:22692271.
  • 25
    Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev, 2010;26:540549.
  • 26
    Pratley RE, Nauck M, Bailey T et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet, 2010;375:14471456.
  • 27
    Pratley R, Nauck M, Bailey T et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract, 2011;65:397407.
  • 28
    Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, Rave K, Kapitza C. Further improvement in postprandial glucose control when adding exenatide (EXE) or sitagliptin (SITA) to combination therapy with insulin glargine (GLAR) and metformin (MET) - a proof-of-concept study. Diabetes Care, 2010;33:15091515.
  • 29
    Violante R, Oliveira JH, Yoon KH et al. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with Type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin. Diabet Med, 2012;29:e417e424.
  • 30
    Bergenstal RM, Wysham C, Macconell L et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet, 2010;376:431439.
  • 31
    Best JH, Rubin RR, Peyrot M, Li Y, Yan P, Malloy J, Garrison LP. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care, 2011;34:314319.
  • 32
    Schmidt WE, Christiansen JS, Hammer M, Zychma MJ, Buse JB. Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study. Diabet Med, 2011;28:715723.
  • 33
    Ridge T, Moretto T, Macconell L, Pencek R, Han J, Schulteis C, Porter L. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes. Diabetes Obes Metab, 2012;. doi:10.1111/j.1463-1326.2012.01639.x.
  • 34
    Davies M, Pratley R, Hammer M, Thomsen AB, Cuddihy R. Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin. Diabet Med, 2011;28:333337.
  • 35
    Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenen M, Hussein MA. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the GLP-1 receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care, 2010;34:9095.
  • 36
    Nauck MA, Duran S, Kim D et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia, 2007;50:259267.
  • 37
    Russell-Jones D, Vaag A, Schmitz O et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia, 2009;52:20462055.
  • 38
    Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, Woerle HJ. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab, 2011;13:6574.
  • 39
    ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008;358:25452559.
  • 40
    ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 2008;358:25602572.
  • 41
    Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med, 2009;360:129139.
  • 42
    Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia, 2009;52:22882298.
  • 43
    Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol, 2008;48:592598.
  • 44
    Shah Z, Pineda C, Kampfrath T et al. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vasc Pharmacol, 2011;55:29.
  • 45
    Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension, 2010;56:728733.
  • 46
    Boschmann M, Engeli S, Dobberstein K et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab, 2009;94:846852.
  • 47
    Matikainen N, Mänttäri S, Schweizer A et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia, 2006;49:20492057.
  • 48
    Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care, 2010;33:17591765.
  • 49
    Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev, 2012;33:187215.
  • 50
    DeVries JH, Bain SC, Rodbard HW et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care, 2012;35:14461454.
  • 51
    Buse JB, Bergenstal RM, Glass LC et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med, 2011;154:103112.
  • 52
    Thong KY, Jose B, Blann AD et al. Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Diabetes Res Clin Pract, 2011;93:e87e91.
  • 53
    Hong ES, Khang AR, Yoon JW et al. Comparison between sitagliptin as add-on therapy to insulin and Insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab, 2012;14:795802.
  • 54
    Vilsboll T, Rosenstock J, Yki-Jarvinen H et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab, 2010;12:167177.
  • 55
    Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin, 2012;28:513523.
  • 56
    McGill JB, Sloan L, Newman J, Patel S, Sauce C, von Eynatten M, Woerle HJ. (2012) Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care, [Epub ahead of print].
  • 57
    Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes, 2012;6:4146.
  • 58
    Lane W, Weinrib S, Rappaport J. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Technol Ther, 2011;13:592595.
  • 59
    Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract, 2007;13:444450.
  • 60
    Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther, 2009;31:15111523.
  • 61
    Thong KY, Jose B, Sukumar N et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Diabetes Obes Metab, 2011;13:703710.
  • 62
    Rosenstock J, Shenouda SK, Bergenstal RM et al. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care, 2012;35:955958.
  • 63
    Levin PA, Mersey JH, Zhou S, Bromberger LA. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes. Endocr Pract, 2012;18:1725.
  • 64
    Levin P, Wei W, Wang L, Pan C, Douglas D, Baser O. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes. Curr Med Res Opin, 2012;28:439446.
  • 65
    Pawaskar MD, Blickensderfer AL, Hoogwerf BJ, Quimbo R, Wade R. Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy. J Med Econ, 2011;14:705708.
  • 66
    Sheffield CA, Kane MP, Busch RS, Bakst G, Abelseth JM, Hamilton RA. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract, 2008;14:285292.
  • 67
    Morrow L, Hompesch M, Guthrie H, Chang D, Chatterjee DJ. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes Obes Metab, 2011;13:7580.
  • 68
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab, 2007;9:733745.
  • 69
    Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin, 2008;24:489496.
  • 70
    Shah ND, Mullan RJ, Breslin M, Yawn BP, Ting HH, Montori VM. Translating comparative effectiveness into practice: the case of diabetes medications. Med Care, 2010;48:S153S158.
  • 71
    Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med, 2011;154:554559.
  • 72
    Meneghini LF, Orozco-Beltran D, Khunti K et al. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab, 2011;96:33373353.
  • 73
    Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract, 2009;15:540559.
  • 74
    Schernthaner G, Guerci B, Gallwitz B, Rose L, Nicolay C, Kraus P, Kazda C. Impact of postprandial and fasting glucose concentrations on HbA(1c) in patients with type 2 diabetes. Diabetes Metab, 2010;36:389394.
  • 75
    Woerle HJ, Neumann C, Zschau S et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract, 2007;77:280285.
  • 76
    Januvia. Januvia® (sitagliptin) tablets [prescribing information]. Whitehouse, NJ: Merck & Co., 2010.
  • 77
    Boulton DW, Li L, Frevert EU et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet, 2011;50:253265.
  • 78
    Chacra AR. Saxagliptin for type 2 diabetes. Diabetes Metab Syndr Obes, 2010;3:325335.
  • 79
    Victoza. Victoza® (liraglutide [rDNA origin] injection), solution for subcutaneous use [prescribing information]. Princeton, NJ: Novo Nordisk Inc., 2011.
  • 80
    Byetta. Byetta® (exenatide) injection [prescribing information]. San Diego, CA: Amylin Pharmaceuticals, 2011.
  • 81
    Bydureon. Bydureon (exenatide extended-release for injectable suspension) [prescribing information]. San Diego, CA: Amylin Pharmaceuticals, 2012.
  • 82
    Campbell RK. Recommendations for improving adherence to type 2 diabetes mellitus therapy–focus on optimizing insulin-based therapy. Am J Manag Care, 2012;18:S55S61.
  • 83
    Triplitt C, Chiquette E. Exenatide: from the Gila monster to the pharmacy. J Am Pharm Assoc, 2006;46:4452.
  • 84
    Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab, 2011;13:144149.